🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Cathie Wood's ARK sells Zoom stock, buys 10X Genomics in major trades

EditorAhmed Abdulazez Abdulkadir
Published 15/07/2024, 10:28
©  Reuters
ZM
-
TXG
-

Investors following Cathie Wood's ARK ETFs witnessed a significant shift in the company's portfolio on Friday, July 12, 2024, with a major buy in 10X Genomics Inc (NASDAQ:TXG) and a substantial sell of Zoom Video Communications Inc (NASDAQ:ZM).

ARK's largest transaction for the day was the purchase of 440,689 shares of 10X Genomics, a life science technology company, valued at approximately $7,487,306. This move was spread across two of its funds, with 361,804 shares bought through ARKK and 78,885 shares through ARKG. The consistent buying pattern of 10X Genomics stock by ARK over the past week suggests a strong conviction in the company's long-term growth potential.

Conversely, ARK sold 195,490 shares of the popular video conferencing platform, Zoom Video Communications, for a total value of $11,064,733, all through its ARKK ETF. This sale marks a continuation of ARK's recent trend of reducing its position in Zoom, which has been observed in the previous trading days.

Another notable transaction was the sale of 21,517 shares of Incyte Corp (NASDAQ:INCY), a biopharmaceutical company, through its ARKG ETF, totaling $1,340,293. This follows a pattern of selling Incyte shares noted in the previous week's trades.

In addition, ARK divested 49,753 shares of Veracyte Inc (NASDAQ:VCYT), a genomic diagnostics company, for a value of $1,122,925 through its ARKW ETF. This sale comes after a purchase of Veracyte shares earlier in the week, indicating a possible rebalancing strategy.

Smaller trades included the sale of 2,046 shares of Coinbase Global Inc (NASDAQ:COIN) through ARKF for $439,132, and the sale of 2,188 shares of Verve Therapeutics Inc (NASDAQ:VERV) through ARKK for $13,937. Furthermore, ARK sold 16,353 shares of Velo3D Inc (NYSE:NYSE:VLD) for $50,367, distributed between ARKQ and ARKX ETFs.

Lastly, ARK reduced its holdings in Ginkgo Bioworks Holdings Inc (NYSE:NYSE:DNA) by 236 shares for a modest $75 through its ARKK ETF, indicating a minimal change in position for this stock.

Investors and analysts closely monitor ARK's daily trades to gain insights into Cathie Wood's investment strategy and to understand the broader trends that may be developing in the innovative sectors that ARK targets.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.